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The worst Ebola virus (EV) outbreak in history has hit Liberia, Sierra Leone and Guinea
hardest and the trend lines in this crisis are grave, and now represents a global public
health threat concern. Limited therapeutic and/or prophylactic options are available for
people suffering from Ebola virus disease (EVD) and further complicate the situation.
Previous studies suggested that the EV glycoprotein (GP) is the main determinant
causing structural damage of endothelial cells that triggers the hemorrhagic diathesis,
but molecular mechanisms underlying this phenomenon remains elusive. Using the
informational spectrum method (ISM), a virtual spectroscopy method for analysis of the
protein-protein interactions, the interaction of GP with endothelial extracellular matrix
(ECM) was investigated. Presented results of this in silico study suggest that Elastin
Microfibril Interface Located Proteins (EMILINs) are involved in interaction between GP
and ECM. This finding could contribute to a better understanding of EV/endothelium
interaction and its role in pathogenesis, prevention and therapy of EVD.
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INTRODUCTION
Ebola virus (EBOV) is an aggressive pathogen that causes a
highly lethal hemorrhagic fever syndrome in humans and non-
human primates with mortality rates ranging from 50 to 90%
(Peters and Khan, 1999). EBOV belongs to the Filoviridae, order
Mononehavirales. The members of this genus of ssRNA viruses
are called ebolaviruses and include five known virus species:
Bundibugyo virus (BDBV), Sudan virus (SUDV), Taï Forest virus
(TAFV), Reston virus (REBOV) and one called simply Ebola
virus (EBOV, formerly Zaire Ebola virus) which caused a num-
ber of outbreaks during the past 40 years. The current outbreak
began in December 2013 in Guinea and spread into Liberia,
Sierra Leone and Nigeria, and is the largest known EV disease
(EVD) outbreak; that, at the beginning was not adequately con-
trolled and now represents a global public health threat concern
(Gire et al., 2014). In our previous work, we studied the phy-
logeography of EBOV and found the origin of EBOV 2014 to
be strains from 1976 in Zaire. This origin ultimately seeded a
basal clade that became extinct while also maintaining a 25-year
lineage in Gabon. We also found that the Guinea and Sierra
Leone viruses are descendants of an earlier outbreak in Gabon
that also spread to Democratic Republic Congo (Gire et al.,
2014).
Disseminated intravascular coagulation (DIC) is a prominent
manifestation of EBOV infection (Baskerville et al., 1985). DIC is
a syndrome characterized by coagulation abnormalities includ-
ing systemic intravascular activation of coagulation leading to
widespread deposition of fibrin in the circulation. It is imperative
to understand the molecular mechanisms underlying this phe-
nomenon and other processes involved in the pathogenesis of the
disease in order to develop an efficient therapy and/or vaccine.
Despite extensive research on EVD, many questions concerning
the virus host interaction of EBOV remain open. This also con-
cerns the important question of the role of endothelial cells in
the pathogenesis of EBOV hemorrhagic fever (HF). The EBOV
infection of endothelial cells has been well documented in non-
human primates (Baskerville et al., 1985; Geisbert et al., 1992;
Jaax et al., 1996; Davis et al., 1997; Ryabchikova et al., 1999).
It was shown that plasma or serum from convalescing patients
enhanced this infection and that this enhancement was mediated
by antibodies to the viral glycoprotein (GP) and by the com-
plement component C1q (Takada et al., 2001, 2003). Previous
studies suggested that the EBOV glycoprotein (GP) is the main
determinant of vascular cell injury and leads to direct structural
damage of endothelial cells that triggers the hemorrhagic diathe-
sis (Yang et al., 1998, 2000). It has been shown that abnormalities
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associated with EBOV HF are not directly caused by cytolysis of
endothelial cells but rather by an indirect mechanism (Geisbert
et al., 2003).
Previously, we studied the interactions between the anthrax
protective antigen (PA) from Bacillus anthraces and target host
proteins by in silico applying the informational spectrum method
(ISM) and by in vitro assays (Doliana et al., 2008). Our find-
ings suggested that the PA interaction with the cell surface
receptor is not sufficient to explain the vascular lesions and
prominent hemorrhages caused by Bacillus anthracis. We pro-
posed a role for the vascular associated proteins such as EMILINs
(Elastin Microfibril Interface Located Protein) which could func-
tion as potential “decoy receptor binding proteins” (Doliana et al.,
2008).
Here we investigated possible interaction between EBOV GP
and EMILINs using the ISM technique. Results of this in silico
study suggest that EMILINs are involved in interaction between
EBOV and the endothelial extracellular matrix (ECM). We dis-
cuss implications of possible GP/EMILIN interaction in EVD
pathogenesis, prevention and therapy.
MATERIALS AND METHODS
VIRUS SEQUENCES
Sixteen non-redundant GP1 sequences from Ebola virus col-
lected during outbreaks from 1976 to 2014 have been investigated
(Data Sheet 1) and 101 GP1 sequences from the EBOV outbreak
2014 (Data Sheet 2). All sequences were taken from GenBank
and UniProt databases and their accession numbers are given in
Data Sheet 1 and Data Sheet 2.
ELECTRON-ION INTERACTION POTENTIAL (EIIP)
The intermolecular interactions in biological systems encompass
two basic steps, (i) specific long-distance targeting of interacting
molecules and (ii) chemical bond formation between interacting
molecules. The first step is determined by selective long-range
forces which are efficient at a distance longer than one lin-
ear dimension of the interacting macromolecules (102-103 Å′)
(Fröhlich, 1968, 1970, 1975). These forces directly influence num-
ber of productive collisions between interacting molecules. Before
chemical bond formation take place, reacting molecular regions
must be positioned close enough (at a distance of ≈2 Å) and the
appropriate atoms must be held in the correct orientation for the
reaction that is to follow, because the attractive forces involved
in the recognition and binding of molecules include all the weak
non-covalent forces (van der Waals, hydrogen bonding, ionic
interactions, etc.). For this reason, stereochemical complemen-
tarity between interacting molecules is essential for the second
step.
It has been proposed that the number of valence electrons
and the electron-ion interaction potential (EIIP) representing
the main energy term of valence electrons are essential physical
parameters determining of the long-range properties of bio-
logical molecules (Veljkovic, 1980). We showed (Veljkovic and
Lalovic, 1976; Veljkovic, 1980) that EIIP can be determined for
organic molecules by the following simple equation derived from
the “general model pseudopotential” (Veljkovic and Slavic, 1972;
Veljkovic, 1973; Veljkovic and Lalovic, 1973),
W = 0.25Z
∗ sin (1.04πZ∗)
2π
(1)
where Z∗ is the average quasivalence number (AQVN) deter-
mined by
Z∗ = 1
N
m∑
i= 1
niZi (2)
where Zi is the valence number of the i-th atomic component, ni
is the number of atoms of the i-th component, m is the number
of atomic components in the molecule, and Nis the total number
of atoms. The EIIP values calculated according to Equations (1)
and (2) are given in Rydberg (Ry).
INFORMATIONAL SPECTRUMMETHOD (ISM)
The informational spectrum method (ISM) technique (Veljkovic
et al., 1985; Veljkovic and Cosic, 1987; Lazovic, 1996; Cosic, 1997)
is based on a model of the primary structure of a protein using
a sequence of numbers, by assigning to each amino acid the
corresponding value of EIIP (Table 1). The obtained numerical
sequence, is subjected to a discrete Fourier transformation which
is defined as follows,
X(n) =
N∑
m= 1
x(m)e−i2πn(m−1)/N , n = 1, 2, ...,N/2 (3)
where x(m) is the m-th member of a given numerical series, N is
the total number of points in this series, and X(n) are discrete
Fourier transformation coefficients. These coefficients describe
the amplitude, phase and frequency of sinusoids, which com-
prised the original signal. The absolute value of complex discrete
Fourier transformation defines the amplitude spectrum and the
phase spectrum. The complete information about the original
sequence is contained in both spectral functions. However, in the
case of protein analysis, relevant information is presented in an
energy density spectrum (Veljkovic et al., 1985), which is defined
as follows,
S(n) = X(n)X∗(n) = |X(n)|2, n = 1, 2, ...,N/2 (4)
In this way, sequences are analyzed as discrete signals. It is
assumed that their points are equidistant with the distance d = 1.
The maximal frequency in a spectrum defined in this way is
F = 1/2 d = 0.5. The frequency range is independent of the total
number of points in the sequence. The total number of points in a
sequence influences only resolution of the spectrum. The resolu-
tion of the N-point sequence is 1/n. The n-th point in the spectral
function corresponds to a frequency f(n) = nf = n/N. Thus, the
initial information defined by the sequence of amino acids can
now be presented in the form of the informational spectrum (IS),
representing the series of frequencies and their amplitudes. The
schematic presentation of the ISM is given in Figure 1.
The IS frequencies correspond to the distribution of structural
motifs with defined physico-chemical characteristics responsible
for biological function of a protein. When comparing proteins
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which share the same biological or biochemical function, the ISM
technique allows detection of code/frequency pairs which are spe-
cific for their common biological properties, or which correlate
with their specific interaction. This common informational
Table 1 | The electron-ion interaction potential (EIIP) used to encode
amino acids.
Amino acid EIIP [Ry]
Leu 0.0000
Ile 0.0000
Asn 0.0036
Gly 0.0050
Glu 0.0057
Val 0.0058
Pro 0.0198
His 0.0242
Lys 0.0371
Ala 0.0373
Tyr 0.0516
Trp 0.0548
Gln 0.0761
Met 0.0823
Ser 0.0829
Cys 0.0829
Thr 0.0941
Phe 0.0946
Arg 0.0959
Asp 0.1263
characteristics of sequences is determined by cross-spectrum or
consensus informational spectrum (CIS). A CIS of N spectra is
obtained by the following equation,
C(j) =
N∏
i= 1
S(i, j) (5)
where S(i,j) is the j-th element of the i-th power spectrum and
C(j) is the j-th element of CIS. Thus, CIS is the Fourier trans-
form of the correlation function for the spectrum. In this way,
any spectral component (frequency) not present in all compared
ISs is eliminated. Peak frequencies in CIS are common frequency
components for the analyzed sequences. A measure of similarity
for each peak is a signal-to-noise ratio (S/N), which represents a
ratio between signal intensity at one particular frequency and the
main value of the whole spectrum. If one calculates a CIS for a two
or more of proteins, which have different primary structures, and
finds strictly defined peak frequencies, it means that the analyzed
proteins participate in mutual interactions or have a common
biological function. The characteristic frequencies are, up to now,
obtained for the more than 20 groups of proteins (oncogenes,
kinases, interferons, growth factors, haemoglobins, etc.) as well
as for several types of DNA regulatory sequences (promotors,
terminators, enhancers, SOS-operators) (Cosic, 1997).
The ISM was successfully applied in structure-function analy-
sis of different protein sequences, as well as in de novo design of
biologically active peptides (Huang et al., 2005; Veljkovic et al.,
2008, 2009a,b, 2014; Tintori et al., 2010; Pirogova et al., 2011,
FIGURE 1 | The schematic presentation of the ISM.
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2012; Glisic et al., 2012; Nwankwo, 2013; Srdic-Rajic et al., 2013;
Deng and Huang, 2014).
GP1 RECEPTOR MODELING
The full sequence of GP1 was retrieved from GenBank, acce-
sion number: AIE11800 and modeled on Phyre 2 server (Protein
Homology/analogY Recognition Engine V 2.0) (Kelley and
Sternberg, 2009). The sequence is automatically searched for
homologs, and if found, the 3D coordinates of model are built
according to known crystal structures. The sequence was rec-
ognized and aligned with the crystal structure of Ebola virus
glycoprotein, PDBID 3CSY (Lee et al., 2008). Known regions were
modeled according to known coordinates of the crystal structure,
while the remaining regions were ab initio modeled. The model-
ing was carried out under intensive mode. The confidence in the
model was 47% for 220 and >90% accuracy.
LIGAND OPTIMIZATION
Ligands were built in VEGA ZZ (Pedretti et al., 2004), proto-
nated according to physiological conditions and optimized on
PM6 level of theory using MOPAC 2009.
MOLECULAR DOCKING
Ligand and receptor were prepared using AutoDock Tools 1.5.7.
(Sanner, 1999; Morris et al., 2009). The docking was carried with
Autodock Vina 1.1.2. (Trott and Olson, 2010) The whole receptor
conformational space was searched, using grid box dimensions
60 × 60 × 60 Å3. After selection of conformations that were
docked near recognized sequences important for binding of anti-
malarials, the binding pocket was recognized, grid box centerd
to occupy close amino acid residues and set to dimensions of
20 × 20 × 20 Å3. The docking was carried out with and with-
out weighting of hydrophilic interactions. In case of hydrophilic
weighting, the value was set to −1.20 (compared to default
weight_hydrogen = −0.587439 value). The exhaustiveness was
set to 250.
RESULTS
Complement component C1q and Ebola virus GP1 are involved
in the antibody-dependent enhancement (ADE) of the infection
(Takada et al., 2001, 2003). Previously, we showed that proteins
that are recognized by the same antibody encode for common
information determining the long-range recognition and target-
ing (interaction on distances >5 Å) of this antibody (Veljkovic
et al., 2003; Vergara-Alert et al., 2012). This information is rep-
resented by frequencie(s) in the informational cross-spectrum
(CS) of immunologicaly crossreactive proteins. Efficacy of recog-
nition and targeting of crossreactive proteins by the antibody is
determined with the amplitude and S/N values corresponding
to the common frequency. To identify the common information
encoded by EBOV GP1 and C1q, ISM analysis was performed
on all non-redundant EBOV-2014 GP1 amino acid sequences
in GenBank (Data Sheet 2). Figure 2A shows CS of C1q and
GP1 of EBOV strains KM233035, representing 99 of 101 GP1
homologous sequences from the outbreak 2014 in GenBank
(Data Sheet 2), as well as KJ660346 and KJ660348. This CS is
characterized by a single peak corresponding to the IS frequency
F(0.338), which represents the common information encoded by
FIGURE 2 | Cross-spectral analysis of EBOV-2014 GP1, EMILINs and
C1q. (A) CS of C1q and EBOV-2014; (B) CS of C1q and EMILIN-1, EMILIN-2
and EMILIN-3; (C) CS of EBOV-2014 GP1 and EMILIN-1, EMILIN-2 and
EMILIN-3.
primary structures of GP1 and C1q. This result suggests possi-
ble crossreactivity between these proteins, but also their direct
mutual interaction.
It has been reported that elastin microfibrillar interface
proteins (EMILINs), which are predominantly expressed in
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the ECM, share the C-terminal gC1q domain typical of the
gC1q/TNFsuperfamily members (Colombatti et al., 2012). The
CS of C1qc, representing the major constituent of the human
complement subcomponent C1q, and of EMILINs shows that
these proteins share dominant information which is represented
by the IS frequency F(0.338) (Figure 2B). The CS of EBOV-2014
GP1 (KM233035) and EMILINs contains the dominant peak
at the frequency F(0.338), representing the common informa-
tion encoded by these viral and human proteins (Figure 2C).
The prominent peaks in CSs of EBOV GP1 (KM233035) and
EMILIN-1, EMILIN-2 and EMILIN-3 are also at frequency
F(0.338) (Figure 3). These results of Figures 2, 3 suggest puta-
tive direct interaction or immunological cross-reactivity between
EBOV GP1 and EMILINs.
To identify the domain which is essential for information cor-
responding to the IS frequency F(0.338), the computer scanning of
the primary structure of EBOV GP1 (KM233035) with peptides
of different lengths was performed. This analysis showed that
the main contribution to the frequency F(0.338) comes primarily
from the domain 341-375 (a.a. numbering in maturated protein
without 32 residues of the signal peptide) (Figure 4A). According
to the ISM concept, this region of GP1 (denoted VINEBOV1)
is essential for possible long-range interaction or immunologi-
cal crossreactivity between GP1 and EMILINs. Previously it was
shown that domains of proteins which are essential for their long-
range interaction overlap their mutual binding site or that they
are located in its vicinity (Veljkovic et al., 2009a,b; Colombatti
et al., 2012; Vergara-Alert et al., 2012). Figure 4B shows the IS of
VINEBOV1 containing the dominant peak at the frequency F(0.338).
Effect of ADE varies according the Ebola virus species (Takada
et al., 2003) indicating that properties of GP1 which corre-
spond to information represented by the IS frequency F(0.338)
may also differ between species. In order to analyze this variation
we performed the ISM-based phylogenetic analysis of all non-
redundant sequences of GP1 in GenBank and UniProt databases
of Ebola viruses collected between 1976 and 2014 (Data Sheet 1)
as described before (Perovic, 2013; Perovic et al., 2013). The
amplitude at the frequency F(0.338) as an parameter in the
ISM-based phylogenetic analysis was used (Perovic et al., 2013)
(Figure 5). The group of four viruses collected between 1994
and 1996 and the EBOV strain KM233035, representing the 99
homologous out of 101 GP1 sequences from the current 2014
outbreak in West Africa, form a distinct cluster in this phyloge-
netic tree. The comparison of IS of GP1 of these viruses shows that
these five viruses have significantly higher values of amplitude and
S/N at the frequency F(0.338) than all other viruses included in
Figure 5 (Table 2). This indicates that interaction/crossreactivity
of these viruses with C1qc/EMILINs is stronger than in the case
of other EBOV. Previously were reportedmutations S3459, L346P,
S390P, P398L, and S408G of GP1 which differ between GP1
of EBOV-1976 and EBOV-1995 (Rodriguez et al., 1999). These
mutations were fixed in all EBOV strains in outbreaks 1994–
1996 although they are located within highly variable domain
of GP1. The homology analysis of GP1 from EBOV collected
during outbreaks from 1994 to 2014 (Data Sheet 3) show that
four mutations S3459, L346P, S390P, P398L are the only ones
present in 99 out of 101 sequences from EBOV-2014. From this
FIGURE 3 | Cross-spectra of EMILINs and GP1 from EBOV-2014
KM233035. (A) CS of EMILIN-1 and GP1 KM233035; (B) CS of EMILIN-2
and GP1 KM233035; (C) CS of EMILIN-3 and GP1 KM233035.
point of view, EBOV-2014 is the most similar to the EBOV from
outbreaks 1994–1996. Interestingly, the mutation P398L was not
present in any of the GP1 proteins from viruses isolated after
1996 but it re-appeared in EBOV-2014. To assess the potential
biological effect of this mutation we introduced the reverse muta-
tion L398P into GP1 of EBOV KM233035. This change resulted
in a decrease of the amplitude at the frequency F(0.338). This
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FIGURE 4 | Mapping of the putative interacting sites of EBOV-2014
(KM233035) GP1 and EMILINs. (A) Position of the domain VINEBOLA1 in
the primary structure of GP1. (B) IS of the VINEBOLA1 domain (residues
341–375).
reverse mutation also significantly decreased the amplitudes at
two other frequencies F(0.068) and F(0.468) which we previously
reported as important for virus/receptor interaction (Veljkovic
et al., submitted). These in silico results strongly suggested the
biological significance of the mutation P398L which probably
modulates interaction between GP1 and host proteins. Finally
we investigated the effect of the mutation S408G which disap-
peared after 1996. Introduction of this mutation into GP1 from
EBOV KM233035 resulted in a significant change of the IS and
increased the amplitude of the frequency F(0.338) (Figure 6). This
indicates that acquisition of the mutation S408G by EBOV-2014
could increase the interaction/crossreactivity of these viruses with
C1qc/EMILINs.
Systematic screening of 1012 FDA-approved drugs revealed
amodiquine as the best candidate EBOV entry inhibitor (Madrid
et al., 2013). We performed the docking analysis in order to
identify a possible binding site for amodiaquine on EBOV GP1.
After recognition of the protein domain important for binding
of anti-malarials (Thr 341-His 375), the entire protein receptor
conformational space was searched for binding pockets that
include identified amino acids. As mentioned in Materials and
Methods, the search was performed with and without empha-
sized hydrophilic interactions. During the conformational search,
and only in the case of weighted hydrophilic interactions, confor-
mations docked into binding pocket including recognized amino
acids were found. The following amino acid residues were found
to interact with amodiaquine: Pro 352, Asn 354, Ser 355, Gln
289, Ile 286, Pro 283, Asn 281, Glu 440, Asp 353, Phe 162. The
gridbox was then moved and docking procedure was repeated,
with the same parameters, but smaller grid box dimensions). The
docked conformation of amodiaquine with lowest binding energy
is presented on Figure 7. The stabilizing interactions - hydrophilic
(with Asn 281, Ser 355, Asn 354, and Gln 289) and hydropho-
bic (CH-π with Pro 283, Ile 286, and possible aromatic with
Phe 162) are thus formed between three loops, making it possi-
ble to stabilize protein conformation. On the other hand, there is
no salt bridge found between protonated nitrogen and negatively
charged amino acid residues in GP1, although there are candi-
dates, such as Asp 353 or Glu 440, or other similar. Keeping in
mind that the 3D coordinates of the discussed region are based
only on primary structure, this can be only good guidance for
insight into binding of antimalarials to GP1.
DISCUSSION
The EVD is a multisystemic disease which is characterized
by hypotension, generalized fluid distribution balance, lym-
phopenia, coagulopathy, and hemorrhage. The potential role of
endothelial cells in these various pathogenic processes is only
partially understood. It was previously suggested that the EBOV
GP is the main determinant of vascular cell injury and conse-
quently it was proposed that the direct EBOV replication-induced
structural damage of endothelial cells triggers the hemorrhagic
diathesis (Baskerville et al., 1985; Geisbert et al., 1992). On the
other hand, despite GP’s preferential binding to endothelial cells,
EBOV infection does not induce observable levels of apoptosis
either directly or indirectly in endothelial cells neither in vitro nor
in vivo (Geisbert et al., 2003). These results led to the conclusion
that EBOVmediates disruption of endothelia via an indirect route
rather than by direct cytolysis of endothelial cells (Geisbert et al.,
2003). The EBOV GP is a potent activator of endothelial cells
and also induces changes in the endothelial cell barrier function
(Wahl-Jensen et al., 2005).
Proteins interacting with the GP that mediate endothelial
disruption are not yet known. The present results suggest that
EMILINs, expressed predominantly in the vasculature ECM and
distributed throughout the blood vessel walls (for review see:
Colombatti et al., 2012) are candidate binding proteins of GP1
binding. By applying the ISM analysis on the human pro-
teome, we identified EMILINs as strong binding proteins of
the protective antigen (PA) from B. anthracis and this in sil-
ico predicted interaction was experimentally confirmed in vitro
(Fröhlich, 1968). We suggested that EMILINs, which are par-
ticularly expressed at and underneath the endothelium and in
the vascular smooth muscle, could represent elective sites for
B. anthracis tissue deposition. Consequently, B. anthracis could be
concentrated at this site to play a direct role in the vascular lesions
which are responsible for the prominent focal hemorrhages for
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FIGURE 5 | The ISM-based phylogenetic analysis of non-redundant EBOV GP1.
Table 2 | The amplitude and S/N values at the frequency F(0.338) in IS
of GP1 from EBOV collected 1976-2014.
EBOV (Access. No.) Year Amplitude S/N
AHC70246 1976 3.6 4.6
AGB56749 1977 3.6 4.6
U77384 1994 4.6 5.8
AGB56821 1995 4.9 6.2
AGB56767 1996 4.6 5.9
AGB56776 1996 4.5 5.8
AGB56830 1996 3.8 4.8
EU051632 2001 4.1 5.2
EU051630 2002 3.7 4.8
EU051633 2003 3.8 4.9
EU051634 2005 4.0 5.2
AGB56713 2007 3.7 4.8
HQ613402 2008 3.7 4.8
KM233035 2014 4.6 5.9
KJ660346 2014 4.1 5.3
KJ660348 2014 4.1 5.2
(Data Sheet 1).
human inhalational anthrax (Mayer et al., 2001) and for the
injuries of aorta in similarly affected patients (Mayer et al., 2001;
Holty et al., 2006). Similarly, EMILINs could function as elective
sites for EBOV, thus facilitating infection of endothelial cells.
A prominent manifestation of EBOV infection is DIC, a
syndrome characterized by systemic intravascular activation of
coagulation generalized deposition of fibrin in the circulation
(Sullivan et al., 2003). While EMILINs are known to play a
role in coagulation, as a component of the vessel wall and/or a
component of the thrombus (Sa et al., 2010; Sa and Hoover-Plow,
2011), these proteins could also be involved in DIC through
interaction with GP1. EMILINs also play an important role in
maintaining of ECM and vascular homeostasis (Colombatti et al.,
2012). It was showed that EMILIN1 has the suppressive role in
proteolytic degradation of ECM. This role is associated to both
“structural” and “signaling mediated” functions of this protein
(Danussi et al., 2012). Binding of GP to EMILIN1 could inhibit
this protective function and allow ECMdegradation. In general, it
could be hypothesized that binding of GP to EMILINs contributes
to EBOV infection and EVD pathogenesis by perturbation ECM
and vascular homeostasis.
Computer-assisted scanning of the GP1 sequence indicated
that the domain VINEBOV1 (residues 341–375) was the most
important domain for a strong signal at the frequency F(0.338).
According to the ISM concept, this domain would be involved in
the direct interaction or immunological crossreactivity between
EBOV GP1 and EMILINs. For this reason, VINEBOV1 could be
considered as a possible target for vaccination and treatment
of EVD.
The ISM-based phylogenetic analysis (Figure 5) showed that
GP1 of EBOV-2014 from Sierra Leone represented by virus
KM233035 clusterized with EBOV from 1994-1996 outbreaks,
and that the other two viruses KJ660346 and KJ660348 from
Guinea 2014 are grouped with EBOV from more recent out-
breaks. These results suggested different levels of interaction
between these two groups of EBOV and EMILINs. The homol-
ogy analysis of the highly variable region of GP1 (Rodriguez et al.,
1999) showed that KM233035 was themost similar to EBOV from
outbreaks 1994–1996 (Data Sheet 4).
It has been speculated that EBOV may rapidly accumu-
late mutations during passages in the human host, resulting
in attenuation of the virus by the later stages of an outbreak
(Rodriguez et al., 1999). Contrary to this assumption, it was
shown that GP1 from EBOV-1995 in its highly variable region
acquired mutation S345P, L346P, S390P, P398L, and S408G in
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FIGURE 6 | Effect of the mutation S408G on IS of EBOV-2014
(KM233035) GP1. (A) IS of GP1 from EBOV-2014 (KM233035). (B) IS of
EBOV-2014 (KM233035) GP1 with the mutation S408G.
this highly variable region that unexpectedly remained con-
served after numerous human-to-human passages of the virus
(Rodriguez et al., 1999). These five mutations, which were con-
served as advantageous for the virus, appeared in viruses from
outbreaks 1994 and 1996 (Data Sheet 4). Interestingly, the muta-
tions S345P, L346P, S90P also appeared in viruses from later
EBOV outbreaks; on the contrary, the mutations P398L and
S408G were not present in viruses after 1996, with the only excep-
tion the viruses from the current outbreak 2014 in Sierra Leone.
The GP1 from EBOV contains four of five mutations which
are fixed in viruses from outbreaks 1994–1996 (Data Sheet 4)
and these mutations are present in all 99 viruses from the out-
break 2014 represented with EBOV KM233035. Since the acci-
dental acquisition and fixation of these four mutations within
the highly variable region of GP1 is unlikely, we suggest that
that EBOV from outbreaks in Sierra Leone is more connected
with viruses from outbreaks 1994–1996 than with viruses from
more recent outbreaks, as it was recently suggested (Gire et al.,
2014).
Introduction of mutation S408G, which was absent from all
the EBOV isolates after 1996, into EBOV KM233035 GP1 resulted
in a significant increase of the amplitude at the frequency F(0.338)
(Figure 6). This suggests that acquisition of this mutation by
EBOV during the current outbreak in West Africa could increase
its interaction with ECMs expressing EMILINs, as already pro-
posed by our work for the PA from B. anthracis and EMILINs
(Doliana et al., 2008). By analogy, the increased binding of EBOV
to EMILINs, expressed underneath the endothelium, could result
in higher chances of airborne transmission of EBOV.
Recently published analysis of mutations in EBOV GP protein
revealed 21 SNPs which affect binding of neutralizing antibodies
preventing EBOV infection (Kugelman et al., 2015). Mutations
P398L and S408G are among these SNPs which could influence
prevention and therapy of EVD. These results additionally sup-
port our assumption about significance of these mutations which
could help the virus to avoid the host immune response.
Vaccine against EBOV would be undoubtedly the most effi-
cient way for controlling EBOV outbreaks. Two main obstacles
in development of a vaccine are (i) binding of neutralizing anti-
bodies by soluble GP1 (sGP1) which is in large amount secreted
in the circulation during EBOV infection (antigenic subver-
sion) (Mohan et al., 2012; Basler, 2013), and (ii) the antibody-
dependent enhancement of EBOV infection (ADE) (Takada
et al., 2007). Domain VINEMILIN which possibly is involved in
GP1/EMILINs interaction is not present in sGP1 which is trun-
cated form of GP1. Domain VINEMILIN also not contains epitopes
required for ADE (Takada et al., 2007). Twomonoclonal antibod-
ies (Mabs) which are most effective in neutralization of EBOV are
6D8 Mab and 13F6 Mab (Kugelman et al., 2015). These Mabs are
in the therapeutic cocktail MB-003 which represents one of three
candidate therapeutic formulations for treatment of EVD. The
epitope of 6D8Mab is situated complete within the VIN-EMILIN
peptide and the epitope of 13F6 Mab significantly overlaps this
peptide (Wilson et al., 2000). For these reasons, the region of
GP1 encompassing domain VINEMILIN could be considered as a
candidate antigen for the EBOV vaccine.
Conventional time and money consuming approaches for
drug development (>10 years; >2 billions $) does not meet
the current urgent need for efficacious drugs for treatment of
EBOLA disease. In this situation, an acceptable solution is repur-
posing existing drugs for treatment of EBOV infection, since
currently approved drugs already have well-established safety and
pharmacokinetic profiles in patients, as well as manufacturing
and distribution networks. Recently, Madrid and co-workers per-
formed a systematic screening of 1012 drugs approved in USA
(Madrid et al., 2013) for their activity against EBOV. In this anal-
ysis 24 drugs as candidates for treatment of Ebola disease were
selected. Among these drugs, the most effective are the anti-
malarials amodiaquone, chloroquine, and hydoxychloroquine.
Performed docking analysis showed that amodiaqine possibly
binds the pocket on GP1 which encompasses domain VINEBOV.
In this pocket, residues P352, D353, N354, and S355 directly inter-
act with amodiaquine. Of note also is that not one of residues
which are involved in binding of amodiaquine is within 21 SNPs
affecting therapy of EVD (Kugelman et al., 2015). This sug-
gests the region of EBOV GP1 encompassing domain VINEBOV
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FIGURE 7 | Amodiquine docked into binding pocket of GP1 protein model with designated binding amino acid residues. Residues from domain
important for binding of antimalarics are colored in green.
represents a promising therapeutic target for treatment of EVD
and anti-malarials as candidate drugs which are resistant to
mutation of EBOV.
As a corollary, based on results of in silico analysis of the inter-
action between EBOV GP1 and host proteins, we hypothesizes
(i) that EMILINs could participate in EBOV infection as elec-
tive sites for virus deposition on ECM, (ii) that mutations S3459,
L346P, S390P, P398L, and S408G, are fixed as advantageous in
the highly variable region of GP1 from EBOV isolated during
the outbreaks 1994–1996, and (iii) that the region of EBOV GP1
encompassing domain VINEBOV and anti-malarials that bind to
this region could be considered as a promising therapeutic target
for candidate drugs for the treatment of EVD. These theoreti-
cal predictions, if experimentally confirmed, will help in better
understanding the role of the endothelium in EBOV infection
and could help in development of effective drugs for treatment
of EVD.
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